PROJECT 3: The goal of this project is to prepare for a Phase II trial of recombinant ACE2 in human pulmonary arterial hypertension (PAH) patients. ACE2 is a recently discovered peptide which inactivates Angll to make Ang(1- 7);Ang(1-7) signals through the Masi receptor. ACE2 mechanism and consequences are thus distinct from ACE inhibitors and receptor blockers, as neither result in increased Ang(1-7) and Masi signaling. Recombinant ACE2 has already proven effective in blocking or treating established pulmonary arterial hypertension (PAH) in several rodent models, including in Bmpr2-mutation related PAH, and has already passed safety trials in healthy human subjects. Preliminary data suggests that the mechanism by which ACE2 treats PAH is through reversal of cytoskeletal defects common to both idiopathic and heritable PAH, including defects in steroid hormone receptor shuttling, endothelial barrier function, and cell-cell junctions. In HPAH, these defects are a consequence of all classes of BMPR2 mutation, which regulates the cytoskeleton through binding and phosphorylation of key cytoskeletal regulators LIMK1 and TCTEX1;however, these same defects have also been seen in IPAH, and so we hypothesize that they are a common cause of PAH. Because of the demonstrated safety of ACE2 use in healthy humans and the strong mechanistic and efficacy data in multiple mouse models, we think it is prudent and timely to test ACE2 in PAH patients.
In Aim 1, we propose confirming the molecular mechanism by which ACE2 treats PAH.
In Aim 2, we test the safety of ACE2 for prolonged use and withdrawal in mice.
In Aim 3, we carry out a phase lb, single-center, open- label, dose-escalation and multiple dose study to evaluate the safety and early indications of efficacy of rhACE2 in subjects with PAH. At the conclusion of this project, we anticipate preparation for a Phase II trial of ACE2 in human PAH patients.

Public Health Relevance

Recombinant ACE2 is effective in treating multiple animal models of pulmonary arterial hypertension (PAH), by correcting defects in a pathway, cytoskeletal trafficking, not impacted by any existing treatment for PAH. In this study, we complete studies necessary to translate this finding to human patients, including confirmation of mechanism, long term safety studies, and safety and early efficacy studies in PAH patients.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-Q (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
United States
Zip Code
Meoli, David F; Su, Yan Ru; Brittain, Evan L et al. (2018) The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension. Pulm Circ 8:2045893217745019
Yan, Ling; Cogan, Joy D; Hedges, Lora K et al. (2018) The Y Chromosome Regulates BMPR2 Expression via SRY: A Possible Reason ""Why"" Fewer Males Develop Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 198:1581-1583
Whitaker, Morgan E; Nair, Vineet; Sinari, Shripad et al. (2018) Diabetes Mellitus Associates with Increased Right Ventricular Afterload and Remodeling in Pulmonary Arterial Hypertension. Am J Med 131:702.e7-702.e13
Hemnes, Anna R (2018) Using Omics to Understand and Treat Pulmonary Vascular Disease. Front Med (Lausanne) 5:157
Han, MeiLan K; Arteaga-Solis, Emilio; Blenis, John et al. (2018) Female Sex and Gender in Lung/Sleep Health and Disease. Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease. Am J Respir Crit Care Med 198:850-858
Brittain, Evan L; Thennapan, Thennapan; Maron, Bradley A et al. (2018) Update in Pulmonary Vascular Disease 2016 and 2017. Am J Respir Crit Care Med 198:13-23
Suzuki, Toshio; Carrier, Erica J; Talati, Megha H et al. (2018) Isolation and characterization of endothelial-to-mesenchymal transition cells in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 314:L118-L126
Halliday, Stephen J; Xu, Meng; Thayer, Timothy E et al. (2018) Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension. Pulm Circ 8:2045894018800544
Hemnes, Anna R; Rathinasabapathy, Anandharajan; Austin, Eric A et al. (2018) A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Eur Respir J 51:
Gaskill, Christa F; Carrier, Erica J; Kropski, Jonathan A et al. (2017) Disruption of lineage specification in adult pulmonary mesenchymal progenitor cells promotes microvascular dysfunction. J Clin Invest 127:2262-2276

Showing the most recent 10 out of 56 publications